Home Tags Cardurion Pharmaceuticals

Cardurion Pharmaceuticals

Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has raised a $260 million Series B financing led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital and Digitalis Ventures, as well as existing investors Bain Capital Life Sciences and Bain Capital Private Equity.

[Funding News] Cardurion Pharmaceuticals Raises $260 Million Series B Funding

Team SR -
© Copyright startuprise 2024 All Rights Reserved.
Exit mobile version